# Pharmacogenomic Evaluation of Antihypertensive Responses 2

Study · id `cardio:ct-nct01203852` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01203852](<https://clinicaltrials.gov/study/NCT01203852>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01203852

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 839 participants.

## Technical summary

Registry record NCT01203852. Allocation not applicable; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-05-19.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 839 participants (enrolled count; ClinicalTrials.gov record NCT01203852, source copy `cardio:ctgov-nct01203852-2018-04-06`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01203852, source copy `cardio:ctgov-nct01203852-2018-04-06`, retrieved 2026-10-26)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01203852, source copy `cardio:ctgov-nct01203852-2018-04-06`, retrieved 2026-10-26)
- Completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01203852, source copy `cardio:ctgov-nct01203852-2018-04-06`, retrieved 2026-10-26)
- Results first posted: 2015-05-19 (ClinicalTrials.gov record NCT01203852, source copy `cardio:ctgov-nct01203852-2018-04-06`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01203852, source copy `cardio:ctgov-nct01203852-2018-04-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01203852-2018-04-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pharmacogenomic Evaluation of Antihypertensive Responses 2
- Acronym: PEAR2
- Condition: Hypertension
- Intervention (Drug): Metoprolol
- Intervention (Drug): Chlorthalidone
- Lead sponsor: University of Florida
- Lead sponsor class: OTHER
- Collaborator: National Institute of General Medical Sciences (NIGMS)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Metoprolol (`cardio:metoprolol`)
- Registry intervention name matches this record: Chlorthalidone (`cardio:chlorthalidone`)
- Registry lists this organization as the lead sponsor: University of Florida (`cardio:org-university-of-florida`)

## Provenance

Content hash: 6f7f9c8bef9e7c30c139d7888577bee26eff69add667986de7011103a722fb7a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
